MCID: SPN021
MIFTS: 50

Spinal Meningioma

Categories: Cancer diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Spinal Meningioma

MalaCards integrated aliases for Spinal Meningioma:

Name: Spinal Meningioma 12 20 15 71
Meningioma 44 71
Meningioma, Benign, No Icd-O Subtype 71
Spinal Cord Meningioma 12
Meningioma, Spine 20

Classifications:



External Ids:

Disease Ontology 12 DOID:1138
MeSH 44 D008579
NCIt 50 C6935
SNOMED-CT 67 189167009
UMLS 71 C0025286 C0347515 C1762616

Summaries for Spinal Meningioma

GARD : 20 Spinal meningioma is a rare type of spinal cord cancer. The spinal cord is part of the central nervous system. This tumor often affects middle-aged women. Tumors of the spinal cord can be either primary or arise from other primary tumors (metastatic), and are typically slow growing. The initial signs and symptoms include headache and recent onset of seizures. Other features are motor deficits, sensory deficits, pain, and sphincter dysfunction. The thoracic spine (middle back) is the most common site, followed by the cervical spine (neck). These tumors are rarely seen in the lumbar region (lower back). The only proven risk factor in the development of meningioma is exposure to ionizing radiation. Also, patients with neurofibromatosis type 2 are at increased risk of developing meningioma. Surgery is the treatment of choice and complete tumor removal is reached in the vast majority of patients. The prognosis after surgical resection is excellent.

MalaCards based summary : Spinal Meningioma, also known as meningioma, is related to intraorbital meningioma and lung meningioma. An important gene associated with Spinal Meningioma is NF2 (Neurofibromin 2), and among its related pathways/superpathways are Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 and Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins.. The drugs Thrombin and Tranexamic Acid have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and pituitary, and related phenotypes are Increased Nanog expression and Increased Nanog expression

Related Diseases for Spinal Meningioma

Diseases related to Spinal Meningioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1050)
# Related Disease Score Top Affiliating Genes
1 intraorbital meningioma 32.4 NF2 LZTR1
2 lung meningioma 32.4 PGR NF2
3 rhabdoid meningioma 32.3 TRAF7 SMARCB1 NF2
4 chordoid meningioma 32.3 TRAF7 NF2
5 brain meningioma 32.2 TRAF7 PGR NF2
6 intraventricular meningioma 32.2 TRAF7 NF2
7 skull base meningioma 32.1 TRAF7 SMARCE1 NF2
8 pediatric meningioma 32.1 TRAF7 NF2
9 meningioma, radiation-induced 32.1 TRAF7 SMARCE1 SMARCB1 NF2
10 angiomatous meningioma 32.1 TRAF7 SMARCE1 NF2
11 frontal convexity meningioma 32.1 TRAF7 NF2
12 benign meningioma 32.0 TRAF7 SMARCE1 PGR NF2
13 olfactory groove meningioma 31.9 TRAF7 PGR NF2 LZTR1
14 anterior cranial fossa meningioma 31.7 TRAF7 PGR NF2 LZTR1
15 clear cell meningioma 31.7 TRAF7 SMARCE1 SMARCB1 PGR NF2
16 cerebral falx meningioma 31.7 NF2 NF1
17 optic nerve sheath meningioma 31.5 SMARCB1 NF2 NF1 LZTR1
18 secretory meningioma 31.5 TRAF7 SMARCE1 SMARCB1 NF2
19 monosomy 22 30.9 SMARCB1 NF2
20 psammomatous meningioma 30.8 TRAF7 NF2
21 neurofibromatosis, type i 30.8 SMARCB1 NF2 NF1
22 meningioma, familial 30.6 TRAF7 SMARCE1 SMARCB1 PGR NF2 NF1
23 meningothelial meningioma 30.4 TRAF7 SMARCE1 PGR NF2
24 neuroma 30.2 SMARCB1 NF2 NF1
25 fibrous meningioma 30.1 TRAF7 NF2
26 obstructive hydrocephalus 30.1 NF2 NF1
27 optic nerve glioma 30.0 NF2 NF1
28 chordoid glioma 30.0 PGR NF2
29 neurilemmoma 30.0 SMARCB1 NF2 NF1 LZTR1
30 transitional meningioma 29.8 TRAF7 SMARCE1 PGR NF2
31 neurilemmoma of the fifth cranial nerve 29.6 NF2 NF1 LZTR1
32 benign ependymoma 29.6 NF2 NF1
33 acoustic neuroma 29.5 NF2 NF1 LZTR1
34 basal cell nevus syndrome 29.5 SMARCB1 NF2 NF1
35 skull base cancer 29.4 TRAF7 SMARCE1 PGR NF2
36 li-fraumeni syndrome 29.3 SMARCB1 NF2 NF1
37 corpus callosum lipoma 29.2 SMARCB1 NF2 NF1
38 melanoma, uveal 29.0 PBRM1 NF2 NF1
39 atypical teratoid rhabdoid tumor 29.0 SMARCE1 SMARCC2 SMARCC1 SMARCB1 SMARCA4 NF2
40 plexiform neurofibroma 28.9 NF2 NF1
41 sturge-weber syndrome 28.8 NF2 NF1
42 hypertrichosis 28.8 SMARCE1 SMARCC2 SMARCB1 SMARCA4 ARID1B
43 alacrima, achalasia, and mental retardation syndrome 28.2 SMARCC2 SMARCA4 NF1 ARID1B ACTL6B
44 rhabdoid cancer 27.9 SMARCE1 SMARCC2 SMARCC1 SMARCB1 SMARCA4 PHF10
45 spinal canal and spinal cord meningioma 27.5 TRAF7 SMARCE1 SMARCC2 SMARCC1 SMARCB1 SMARCA4
46 neurilemmomatosis 26.6 SMARCE1 SMARCC2 SMARCC1 SMARCB1 SMARCA4 PHF10
47 intracranial meningioma 11.4
48 childhood brain meningioma 11.3
49 hemangiopericytoma, malignant 11.2
50 cavernous sinus meningioma 11.2

Graphical network of the top 20 diseases related to Spinal Meningioma:



Diseases related to Spinal Meningioma

Symptoms & Phenotypes for Spinal Meningioma

GenomeRNAi Phenotypes related to Spinal Meningioma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased Nanog expression GR00371-A-1 9.43 DPF1 SMARCA4 SMARCB1 SMARCC1 SMARCE1
2 Increased Nanog expression GR00371-A-2 9.43 SMARCE1
3 Increased proliferation GR00094-A 8.62 NF2 SMARCB1

MGI Mouse Phenotypes related to Spinal Meningioma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 embryo MP:0005380 9.86 NF1 NF2 PBRM1 PGR SMARCA4 SMARCB1
2 immune system MP:0005387 9.81 ARID1B NF1 NF2 PBRM1 PGR SMARCA4
3 mortality/aging MP:0010768 9.77 ACTL6B ARID1B LZTR1 NF1 NF2 PBRM1
4 muscle MP:0005369 9.1 ARID1B LZTR1 NF1 PGR SMARCA4 SMARCB1

Drugs & Therapeutics for Spinal Meningioma

Drugs for Spinal Meningioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 148)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Thrombin Approved, Investigational Phase 4
2
Tranexamic Acid Approved Phase 4 1197-18-8 5526
3 Fibrin Tissue Adhesive Phase 4
4 Hemostatics Phase 4
5 Coagulants Phase 4
6 Antifibrinolytic Agents Phase 4
7
Cisatracurium Approved Phase 3 96946-41-7 62887
8
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
9
Sevoflurane Approved, Vet_approved Phase 3 28523-86-6 5206
10
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 3 7487-88-9 24083
11
Propofol Approved, Investigational, Vet_approved Phase 3 2078-54-8 4943
12
Mifepristone Approved, Investigational Phase 3 84371-65-3 55245
13
Progesterone Approved, Vet_approved Phase 3 57-83-0 5994
14
Aminolevulinic acid Approved Phase 3 106-60-5 137
15 Anesthetics Phase 3
16 Antihypertensive Agents Phase 3
17 Vasoconstrictor Agents Phase 3
18 Contraceptive Agents Phase 3
19 Contraceptives, Oral Phase 3
20 Contraceptives, Postcoital Phase 3
21 Progestins Phase 3
22 Dermatologic Agents Phase 3
23 Photosensitizing Agents Phase 3
24
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
25
Hydroxyurea Approved Phase 2 127-07-1 3657
26
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
27
Trabectedin Approved, Investigational Phase 2 114899-77-3 108150
28
Copper Approved, Investigational Phase 1, Phase 2 7440-50-8 27099
29
Verapamil Approved Phase 2 52-53-9 2520
30
Mesna Approved, Investigational Phase 2 3375-50-6 598
31
Fludarabine Approved Phase 2 21679-14-1, 75607-67-9 30751
32
Aldesleukin Approved Phase 2 110942-02-4, 85898-30-2
33
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
34
carbamide peroxide Approved Phase 2 124-43-6
35
nivolumab Approved Phase 2 946414-94-4
36
Ipilimumab Approved Phase 2 477202-00-9
37
Pembrolizumab Approved Phase 2 1374853-91-4
38
Pasireotide Approved Phase 2 396091-73-9 9941444
39
Everolimus Approved Phase 2 159351-69-6 6442177 70789204
40
Bevacizumab Approved, Investigational Phase 2 216974-75-3
41
Ifosfamide Approved Phase 2 3778-73-2 3690
42
Vatalanib Investigational Phase 2 212141-54-3 151194
43
Imidacloprid Vet_approved Phase 1, Phase 2 105827-78-9 86418
44 Cytochrome P-450 Enzyme Inhibitors Phase 2
45 Cytochrome P-450 CYP3A Inhibitors Phase 2
46 Anti-Arrhythmia Agents Phase 2
47 interferons Phase 2
48 Interferon-alpha Phase 2
49 Interferon alpha-2 Phase 2
50 Iron-Dextran Complex Phase 2

Interventional clinical trials:

(show top 50) (show all 143)
# Name Status NCT ID Phase Drugs
1 Neurocognitive Outcome Assessment in Patients With Peri-optic Meningiomas After Excision With Or Without Pealing Of The Outer Layer Of The Cavernous Sinus: A Randomized Controlled Single Blinded Trial. Unknown status NCT03190122 Phase 4
2 Dissection of the Outer Layer of the Lateral Wall of the Cavernous Sinus Decreases Bleeding as Compared to Direct Tumor Attack in Middle Fossa Meningiomas: A Randomized Controlled Trial Unknown status NCT02863484 Phase 4
3 A Prospective, Randomized, Controlled Phase IV Study to Compare Bioseal Versus Standard of Care as an Adjunct to Hemostasis in Elective Brain Tumor Surgery Completed NCT02034799 Phase 4
4 Effect of Tranexamic Acid Infusion to Reduce Intraoperative Blood Loss in Large Meningioma: A Prospective Randomized Double-blind Control Study Not yet recruiting NCT04386642 Phase 4 Tranexamic acid;Placebo
5 PHASE 3 STUDY OF EFFICACY OF TRANEXAMIC ACID IN BRAIN TUMORS RESECTIONS Unknown status NCT01655927 Phase 3 Tranexamic Acid;Placebo: Saline
6 Efficacy of Stereotactic Conformal Radiotherapy (SCRT) Compared to Conventional Radiotherapy in Minimising Late Sequelae in Children and Young Adults With Brain Tumours: a Randomised Clinical Trial Unknown status NCT00517959 Phase 3
7 The Effect of Magnesium Sulphate on Intraoperative Blood Loss in Meningioma Patient Undergoing Craniotomy With Tumor Removal Completed NCT03558516 Phase 3 Magnesium group;Normal saline group
8 Double Blind Randomized Trial of the Anti-Progestational Agent Mifepristone In The Treatment of Unresectable Meningioma Completed NCT03015701 Phase 3 Mifepristone
9 Prospective Study Of Patients With Recurrent Or Incomplete Excised Benign Intercranial Meningiomas For The Evaluation Of Treatment Result With Combined Proton And Photon Irradiation To Doses 55.8 Or 63.0 CGE Completed NCT02947984 Phase 3
10 A Phase 3 Multicenter Study of Gleolan (Aminolevulinic Acid Hydrochloride) to Enhance Visualization of Tumor in Patients With Newly Diagnosed or Recurrent Meningiomas Recruiting NCT04305470 Phase 3 Gleolan (Aminolevulinic Acid Hydrochloride/ALA/ALA-HCI)
11 Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma Recruiting NCT03180268 Phase 3
12 Observation Versus Conventional-Fractionated Radiotherapy or Radiosurgery After Non-radical Surgery for Benign Intracranial Meningiomas: A Phase III Study Terminated NCT00104936 Phase 3
13 Phase II Study of Hydroxyurea for the Treatment of Recurrent and/or Nonoperable Meningioma Unknown status NCT00006119 Phase 2 hydroxyurea
14 Combination of Everolimus and Octreotide LAR in Aggressive Recurrent Meningiomas. Unknown status NCT02333565 Phase 2 Everolimus;Octreotide
15 IMATINIB Plus Hydroxyurea in the Treatment of Recurrent or Progressive Meningiomas: a Randomized Phase II Study Unknown status NCT00904735 Phase 2 hydroxyurea;imatinib mesylate
16 Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma Completed NCT00589784 Phase 2 Sunitinib
17 Phase II Study to Evaluate the Efficacy of Recombinant Interferon-Alpha in the Treatment of Recurrent Unresectable Meningiomas and Malignant Meningiomas Completed NCT00002965 Phase 2
18 Phase II Trial of STI571 (NSC 716051) in Patients With Recurrent Meningioma Completed NCT00045734 Phase 2 imatinib mesylate
19 A Phase II Study of Imatinib Mesylate Plus Hydroxyurea in the Treatment of Patients With Recurrent/Progressive Meningioma Completed NCT00354913 Phase 2 hydroxyurea;imatinib mesylate
20 Phase II Study of Hydroxyurea for Unresectable Meningioma Completed NCT00003590 Phase 2 hydroxyurea
21 ZD1839 FOR Treatment Of Recurrent Or Progressive Malignant Astrocytoma Or Glioblastoma And Recurrent Or Progressive Meningioma: A Phase II Study With A Phase I Component For Patients Receiving EIAEDs Completed NCT00025675 Phase 2 gefitinib
22 Phase II Study of Monthly SOM230C for Recurrent or Progressive Meningioma Completed NCT00859040 Phase 2 SOM230C
23 Trabectedin for Recurrent Grade II or III Meningioma: a Randomized Phase II Study of the EORTC Brain Tumor Group Completed NCT02234050 Phase 2 Trabectedin
24 Peptide Receptor Radionuclide Therapy Administered to Participants With Meningioma With 67Cu-SARTATE™: A Single-centre, Open-label, Non- Randomised, Phase I-IIa Theranostic Clinical Trial Completed NCT03936426 Phase 1, Phase 2 Cu-64 SARTATE and Cu-67 SARTATE
25 Phase II Trial of Bevacizumab in Patients With Recurrent or Progressive Meningiomas Completed NCT01125046 Phase 2
26 A Phase II Trial of PTK-787 in Recurrent or Progressive Meningiomas Completed NCT00348790 Phase 2 vatalanib
27 Combination of Hydroxyurea and Verapamil for Refractory Meningiomas Completed NCT00706810 Phase 2 Hydroxyurea;Verapamil
28 A Single Arm Phase 2 Study of the Dual mTORC1/mTORC2 Inhibitor AZD2014 Provided on an Intermittent Schedule for Neurofibromatosis 2 Patients With Progressive or Symptomatic Meningiomas Completed NCT02831257 Phase 2 AZD2014
29 Phase II Study of Metastatic Cancer That Expresses NY-ESO-1 Using Lymphodepleting Conditioning Followed by Infusion of Anti-NY ESO-1 Murine TCR-Gene Engineered Lymphocytes Completed NCT01967823 Phase 2 Cyclophosphamide;Fludarabine;Aldesleukin
30 Phase I/II Trial of STI571 (NSC 716051) in Patients With Recurrent Malignant Gliomas Completed NCT00010049 Phase 1, Phase 2 imatinib mesylate
31 A Phase I/II Trial of OSI-774 in Patients With Recurrent Malignant Gliomas and Malignant Gliomas Post Radiation Therapy Completed NCT00045110 Phase 1, Phase 2 erlotinib hydrochloride
32 Phase II Trial of Irinotecan in Children With Refractory Solid Tumors Completed NCT00004078 Phase 2 irinotecan hydrochloride
33 Proton Radiation for Low Grade Gliomas Completed NCT01024907 Phase 1, Phase 2
34 A Randomized Phase II Trial of Bevacizumab to Control Brain Radiation Damage Completed NCT00492089 Phase 2 bevacizumab;placebo
35 Effect of Hippocampal Sparing on Neurocognitive Functions and Quality of Live in Patients Irradiated in the Neurocranial Area Recruiting NCT01849484 Phase 2
36 Innovative Trial for Understanding the Impact of Targeted Therapies in NF2 (INTUITT-NF2) Recruiting NCT04374305 Phase 2 Brigatinib
37 A Phase 2 Study of Abemaciclib in Patients With Recurrent Brain Tumors Recruiting NCT03220646 Phase 2 abemaciclib;abemaciclib
38 An Open-Label Phase II Study of Nivolumab in Adult Participants With Recurrent High-Grade Meningioma Recruiting NCT02648997 Phase 2 Nivolumab - 240 mg;Ipilimumab - 1 mg/kg;Nivolumab - 480 mg;Nivolumab - 3 mg/kg
39 A Phase II, Open-label, Single Arm Trial of Pembrolizumab for Refractory Atypical and Anaplastic Meningioma Recruiting NCT03016091 Phase 2 Pembrolizumab
40 Phase II Trial of Pembrolizumab in Recurrent or Residual High Grade Meningioma Recruiting NCT03279692 Phase 2 Pembrolizumab
41 A Prospective, Phase II Study of Lutetium Lu 177 Dotatate (LUTATHERA®) in Patients With Inoperable, Progressive Meningioma After External Beam Radiation Therapy Recruiting NCT04082520 Phase 2 Lutetium Lu 177 Dotatate
42 A Phase 2, Single Arm, Multi-center, Open Label Trial Combining Optune With Concurrent Bevacizumab in the Setting of Recurrent or Progressive Meningioma Recruiting NCT02847559 Phase 2
43 A Phase I/II Study of Nivolumab Plus or Minus Ipilimumab in Combination With Multi-Fraction Stereotactic Radiosurgery for Recurrent High-Grade Radiation-Relapsed Meningioma Recruiting NCT03604978 Phase 1, Phase 2
44 A Single Arm, Open-label, Multicenter Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma Recruiting NCT03971461 Phase 2 Lutathera
45 Phase 2 Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors Recruiting NCT03095248 Phase 2 Selumetinib
46 Phase II, Dosimetry Guided, Peptide Receptor Radiotherapy (PRRT) Using 90Y-DOTA tyr3-Octreotide (90Y-DOTATOC) in Children and Adults With Neuroendocrine and Other Somatostatin Receptor Positive Tumors Recruiting NCT03273712 Phase 2 Amino Acids
47 Phase II Trial of the Immune Checkpoint Inhibitor Nivolumab in Patients With Select Rare CNS Cancers Recruiting NCT03173950 Phase 2 Nivolumab
48 Phase II Trial of Observation for Low-Risk Meningiomas and of Radiotherapy for Intermediate- and High-Risk Meningiomas Active, not recruiting NCT00895622 Phase 2
49 Adjuvant Postoperative High-Dose Radiotherapy for Atypical and Malignant Meningioma: a Phase-II and Observation Study Active, not recruiting NCT00626730 Phase 2
50 Feasibility and Phase II Study Using Proton Radiation For WHO Grade I-III Meningiomas and Hemangiopericytomas Active, not recruiting NCT01117844 Phase 1, Phase 2

Search NIH Clinical Center for Spinal Meningioma

Cochrane evidence based reviews: meningioma

Genetic Tests for Spinal Meningioma

Anatomical Context for Spinal Meningioma

MalaCards organs/tissues related to Spinal Meningioma:

40
Brain, Spinal Cord, Pituitary, Breast, Pineal, Endothelial, Thyroid

Publications for Spinal Meningioma

Articles related to Spinal Meningioma:

(show top 50) (show all 14894)
# Title Authors PMID Year
1
Neurosarcoidosis Masquerading as Giant Cell Arteritis With Incidental Meningioma. 61
32441899 2021
2
Metastases to meningioma-review and meta-analysis. 61
33389125 2021
3
Can Ophthalmologic Examination Predict Abducens Nerve Recovery After Endoscopic Skull Base Surgery? 61
32809233 2021
4
FDG PET/CT of Benign Psammomatous Meningioma Effacing the Medulla. 61
33351510 2021
5
Meningothelial meningioma in an unusual site: Thinking out of the box. 61
33247960 2021
6
Trends in cerebrospinal fluid leak rates following the extended endoscopic endonasal approach for anterior skull base meningioma: a meta-analysis over the last 20 years. 61
33188605 2021
7
Metformin enhances anti-cancer effects of cisplatin in meningioma through AMPK-mTOR signaling pathways. 61
33575476 2021
8
Dilation of the Perioptic Subarachnoid Space Anterior to Optic Nerve Sheath Meningioma. 61
32108115 2021
9
Immunoexpression of epithelial membrane antigen in canine meningioma: Novel results for perspective considerations. 61
32875656 2021
10
YAP1-FAM118B Fusion Defines a Rare Subset of Childhood and Young Adulthood Meningiomas. 61
33074854 2021
11
The endoscope-assisted supraorbital "keyhole" approach for anterior skull base meningiomas: an updated meta-analysis. 61
32889640 2021
12
Clinical outcome after microsurgical resection of intraventricular trigone meningiomas: a single-centre analysis of 20 years and literature overview. 61
32772161 2021
13
Intracranial Autograft Fat Placement to Separate the Optic Chiasm from Tumor to Improve Stereotactic Radiotherapy Dosimetry. 61
33130141 2021
14
Altered Cerebrospinal Fluid (CSF) in Children with Ataxia Telangiectasia. 61
32815118 2021
15
Free tissue transfer for central skull base defect reconstruction: Case series and surgical technique. 61
33592564 2021
16
The incidence of venous thromboembolism following surgical resection of intracranial and intraspinal meningioma. A systematic review and retrospective study. 61
33444944 2021
17
Giant Meningioma in a Patient With Congenital Adrenal Hyperplasia. 61
33229877 2021
18
The protean manifestations of central nervous system IgG4-related hypertrophic pachymeningitis: a report of two cases. 61
33536053 2021
19
Werner Syndrome Protein Expression in Breast Cancer. 61
32919863 2021
20
Relapsed breast cancer complicated by isolated brain metastasis. 61
33598266 2021
21
Meningioma-associated protein 30 accelerates the proliferation and invasion of hepatocellular carcinoma by modulating Wnt/GSK-3β/β-catenin signaling. 61
33405049 2021
22
[Spinal tumors]. 61
33570679 2021
23
A cohort study on adult hematological malignancies and brain tumors in relation to magnetic fields from indoor transformer stations. 61
33601135 2021
24
Multiple Pathways for Pathological Calcification in the Human Body. 61
33274854 2021
25
Poor derivation of Tc-MEP baseline waveforms in surgery for ventral thoracic intradural extramedullary tumor: Efficacy of use of the abductor hallucis in cases with a preoperative non-ambulatory status. 61
33485601 2021
26
Peritumoral brain edema volume in meningioma correlates with tumor fractional anisotropy but not apparent diffusion coefficient or cerebral blood volume. 61
33533947 2021
27
Improved detection of postoperative residual meningioma with [68Ga]Ga-DOTA-TOC PET imaging using a high-resolution research tomograph (HRRT) PET scanner. 61
33526423 2021
28
Menin is necessary for long term maintenance of meningioma-1 driven leukemia. 61
33542482 2021
29
High Mib-1-score correlates with new cranial nerve deficits after surgery for frontal skull base meningioma. 61
31834543 2021
30
Mucosal thickening of the maxillary sinus is frequently associated with diffuse glioma patients and correlates with poor survival prognosis of GBM patients: comparative analysis to meningioma patients. 61
33537891 2021
31
Role of 3-D volume growth rate for drug activity evaluation in meningioma clinical trials: the example of the CEVOREM study. 61
33556177 2021
32
Influence of VEGF-A, VEGFR-1-3, and neuropilin 1-2 on progression-free: and overall survival in WHO grade II and III meningioma patients. 61
33528717 2021
33
Nation-wide Brain Tumor Registry-based Study of Intracranial Meningioma in Japan: Analysis of Surgery-related Risks. 61
33361655 2021
34
Adjuvant Radiotherapy Versus Watchful Waiting for World Health Organization Grade II Atypical Meningioma: A Single-Institution Experience. 61
33582821 2021
35
A Frontal Osteoblastoma in a Middle-Aged Woman Mimicking a Meningioma. 61
32732077 2021
36
Letter to the Editor Regarding "Predictors of Nonroutine Discharge Disposition Among Parasagittal/Parafalcine Meningioma Patients". 61
33607748 2021
37
In Reply to the Letter to the Editor Regarding "Predictors of Nonroutine Discharge Disposition Among Parasagittal/Parafalcine Meningioma Patients". 61
33607749 2021
38
Letter to the Editor. Time to move beyond the Simpson scale in meningioma surgery. 61
33607616 2021
39
Growing Dural Mass That Was Not a Meningioma. 61
32644905 2021
40
Cause-Specific Survival After Meningioma Surgery: A Nationwide Population-Based Competing Risk Study. 61
33096279 2021
41
Primary intraosseous osteolytic meningioma without an evidence of soft tissue invasion. 61
33598256 2021
42
Roles for hENT1 and dCK in gemcitabine sensitivity and malignancy of meningioma. 61
33556172 2021
43
Pineal Region Meningioma in a Very Young Child. 61
33596576 2021
44
Use of high dose cyproterone acetate and risk of intracranial meningioma in women: cohort study. 61
33536184 2021
45
Subcutaneous seeding following surgical excision of an intracranial meningioma in a cat. 61
33588467 2021
46
Preliminary Application of Three-Dimensional Printing Technique in Preoperative Localization of Meningioma in Primary Hospitals. 61
33587526 2021
47
Integration of Different Intraoperative Ultrasound Modalities in Meningioma Surgery: A 4-Step Approach. 61
33607723 2021
48
Adjuvant radiotherapy versus observation following gross total resection for atypical meningioma: a systematic review and meta-analysis. 61
33596974 2021
49
Meningioma with ring enhancement on MRI: a rare case report. 61
33568080 2021
50
Intraparenchymal atypical meningioma in the posterior fossa: a case report and literature review. 61
33595378 2021

Variations for Spinal Meningioma

Expression for Spinal Meningioma

Search GEO for disease gene expression data for Spinal Meningioma.

Pathways for Spinal Meningioma

Pathways related to Spinal Meningioma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.51 SMARCE1 SMARCC2 SMARCC1 SMARCB1 SMARCA4 PBRM1
2
Show member pathways
12.99 SMARCE1 SMARCC2 SMARCC1 SMARCB1 SMARCA4 DPF1
3
Show member pathways
12.6 SMARCE1 SMARCC2 SMARCC1 SMARCB1 SMARCA4 PBRM1
4 12.11 SMARCC2 SMARCC1 SMARCB1 SMARCA4
5
Show member pathways
12.03 SMARCE1 SMARCC2 SMARCC1 SMARCB1 SMARCA4 PHF10
6
Show member pathways
11.89 SMARCE1 SMARCC2 SMARCC1 SMARCB1 SMARCA4
7
Show member pathways
11.59 SMARCC2 SMARCC1 SMARCB1 SMARCA4
8 11.52 SMARCC2 SMARCC1 SMARCA4
9
Show member pathways
11.34 SMARCE1 SMARCC2 SMARCC1 SMARCB1 SMARCA4 ARID1B

GO Terms for Spinal Meningioma

Cellular components related to Spinal Meningioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 10.13 SMARCE1 SMARCC2 SMARCC1 SMARCB1 SMARCA4 PHF10
2 nucleus GO:0005634 10.13 SMARCE1 SMARCC2 SMARCC1 SMARCB1 SMARCA4 PHF10
3 chromatin GO:0000785 9.86 SMARCE1 SMARCC2 SMARCC1 SMARCB1 SMARCA4 PHF10
4 protein-containing complex GO:0032991 9.85 SMARCE1 SMARCC2 SMARCC1 SMARCB1 SMARCA4
5 npBAF complex GO:0071564 9.63 SMARCE1 SMARCC2 SMARCC1 SMARCB1 SMARCA4 PHF10
6 nuclear chromosome GO:0000228 9.58 SMARCE1 SMARCB1 PBRM1
7 SWI/SNF complex GO:0016514 9.5 SMARCE1 SMARCC2 SMARCC1 SMARCB1 SMARCA4 ARID1B
8 XY body GO:0001741 9.43 SMARCC1 SMARCB1
9 brahma complex GO:0035060 9.37 SMARCB1 ARID1B
10 nBAF complex GO:0071565 9.23 SMARCE1 SMARCC2 SMARCC1 SMARCB1 SMARCA4 DPF1

Biological processes related to Spinal Meningioma according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 9.99 SMARCC1 SMARCB1 SMARCA4 PHF10 PGR DPF1
2 regulation of transcription by RNA polymerase II GO:0006357 9.97 SMARCE1 SMARCC2 SMARCC1 SMARCB1 SMARCA4 PGR
3 chromatin organization GO:0006325 9.92 SMARCE1 SMARCC2 SMARCC1 SMARCB1 SMARCA4 PBRM1
4 positive regulation of transcription, DNA-templated GO:0045893 9.91 SMARCE1 SMARCC2 SMARCC1 SMARCA4 ARID1B ACTL6B
5 nervous system development GO:0007399 9.91 SMARCE1 SMARCC2 SMARCC1 SMARCB1 SMARCA4 PHF10
6 negative regulation of transcription, DNA-templated GO:0045892 9.89 SMARCE1 SMARCC2 SMARCA4 PHF10 DPF1
7 negative regulation of cell proliferation GO:0008285 9.84 SMARCB1 PBRM1 NF2 NF1
8 spinal cord development GO:0021510 9.56 NF1 ACTL6B
9 chromatin remodeling GO:0006338 9.56 SMARCE1 SMARCC2 SMARCC1 SMARCB1 SMARCA4 PBRM1
10 negative regulation of MAPK cascade GO:0043409 9.55 NF2 NF1
11 nucleosome disassembly GO:0006337 9.55 SMARCE1 SMARCC2 SMARCC1 SMARCB1 SMARCA4
12 positive regulation by host of viral transcription GO:0043923 9.52 SMARCB1 SMARCA4
13 positive regulation of transcription of nucleolar large rRNA by RNA polymerase I GO:1901838 9.48 SMARCB1 SMARCA4
14 RNA polymerase I preinitiation complex assembly GO:0001188 9.46 SMARCB1 SMARCA4
15 positive regulation of glucose mediated signaling pathway GO:1902661 9.4 SMARCB1 SMARCA4
16 ATP-dependent chromatin remodeling GO:0043044 9.23 SMARCE1 SMARCC2 SMARCC1 SMARCB1 SMARCA4 PBRM1

Molecular functions related to Spinal Meningioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chromatin binding GO:0003682 9.65 SMARCE1 SMARCC2 SMARCC1 PBRM1 ACTL6B
2 transcription coregulator activity GO:0003712 9.61 SMARCB1 PHF10 DPF1
3 protein N-terminus binding GO:0047485 9.58 SMARCE1 SMARCC1 SMARCA4
4 histone binding GO:0042393 9.55 SMARCC2 SMARCC1 SMARCA4 PHF10 DPF1
5 transcription coactivator activity GO:0003713 9.5 SMARCE1 SMARCC2 SMARCC1 SMARCB1 SMARCA4 ARID1B
6 lysine-acetylated histone binding GO:0070577 9.46 SMARCA4 PBRM1
7 Tat protein binding GO:0030957 9.37 SMARCB1 SMARCA4
8 RNA polymerase I CORE element sequence-specific DNA binding GO:0001164 9.32 SMARCB1 SMARCA4
9 nucleosomal DNA binding GO:0031492 9.02 SMARCE1 SMARCC2 SMARCC1 SMARCB1 SMARCA4

Sources for Spinal Meningioma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....